FluCide-I™
Targeted nanoviricide against human influenza. Our development goals include the development of a drug that will have the ability to completely neutralize and disable the viral particles in the bloodstream and lungs. This drug is scheduled for a second series of pre-clinical animal studies at KARD Scientific, Inc, in Wilmington, MA during Q1 of 2007.
|
HepaCide-I™
Our development goals are to produce a targeted nanoviricide that attacks, neutralizes and disables the Hepatitis C virus. Hepatitis C virus is known to attack liver cells and is linked to liver cancer. This drug is currently scheduled to enter pre-clinical animal studies in late 2007.
|
AviFluCide-I™
Our development goals are to develop a drug against bird (avian) influenza. This drug is scheduled for pre-clinical animal studies in Q1 2007.
|
FluCide-HP-I™
Targeted nanoviricide directed against the Highly Pathogenic (most dangerous) form of various influenzas. Our development goals are to neutralize and disable the viral particles in the bloodstream and the lungs. This drug is scheduled for pre-clinical animal studies in Q1 2007.
|
HIVCide-I™
Our development goals are to produce a targeted nanoviricide directed against the HIV viruses. We plan to accelerate development of this drug in Q4 2007.
|
RabiCide-I™
Targeted nanoviricide directed against the rabies virus.
This drug is scheduled to enter pre-clinical animal studies at the National Institute of Hygiene and Epidemiology in Vietnam in early 2007.
|
